Humanwell Healthcare Group Co Ltd Net Assets
Humanwell Healthcare Group Co Ltd net assets. Based on the latest financial reports, Humanwell Healthcare Group Co Ltd (600079) has net assets worth CN¥22.44 Billion CNY (≈ $3.28 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥37.19 Billion ≈ $5.44 Billion USD) and total liabilities (CN¥14.75 Billion ≈ $2.16 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Humanwell Healthcare Group Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥22.44 Billion |
| % of Total Assets | 60.34% |
| Annual Growth Rate | 21.9% |
| 5-Year Change | 40.6% |
| 10-Year Change | 83.65% |
| Growth Volatility | 39.28 |
Net Assets of Humanwell Healthcare Group Co Ltd (1994–2025)
Net assets of Humanwell Healthcare Group Co Ltd from 1994 to 2025. This chart illustrates how Humanwell Healthcare Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See Humanwell Healthcare Group Co Ltd (600079) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Humanwell Healthcare Group Co Ltd (1994–2025)
The table below shows the annual net assets of Humanwell Healthcare Group Co Ltd from 1994 to 2025. For live market cap and overall valuation, see Humanwell Healthcare Group Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥22.01 Billion ≈ $3.22 Billion |
+6.35% |
| 2024-12-31 | CN¥20.69 Billion ≈ $3.03 Billion |
+2.96% |
| 2023-12-31 | CN¥20.10 Billion ≈ $2.94 Billion |
+12.02% |
| 2022-12-31 | CN¥17.94 Billion ≈ $2.63 Billion |
+14.63% |
| 2021-12-31 | CN¥15.65 Billion ≈ $2.29 Billion |
+20.51% |
| 2020-12-31 | CN¥12.99 Billion ≈ $1.90 Billion |
-8.73% |
| 2019-12-31 | CN¥14.23 Billion ≈ $2.08 Billion |
-1.73% |
| 2018-12-31 | CN¥14.48 Billion ≈ $2.12 Billion |
-14.03% |
| 2017-12-31 | CN¥16.85 Billion ≈ $2.47 Billion |
+40.58% |
| 2016-12-31 | CN¥11.98 Billion ≈ $1.75 Billion |
+30.50% |
| 2015-12-31 | CN¥9.18 Billion ≈ $1.34 Billion |
+60.31% |
| 2014-12-31 | CN¥5.73 Billion ≈ $838.16 Million |
+12.74% |
| 2013-12-31 | CN¥5.08 Billion ≈ $743.41 Million |
+39.20% |
| 2012-12-31 | CN¥3.65 Billion ≈ $534.05 Million |
+16.27% |
| 2011-12-31 | CN¥3.14 Billion ≈ $459.33 Million |
+34.86% |
| 2010-12-31 | CN¥2.33 Billion ≈ $340.61 Million |
+11.86% |
| 2009-12-31 | CN¥2.08 Billion ≈ $304.49 Million |
+67.79% |
| 2008-12-31 | CN¥1.24 Billion ≈ $181.47 Million |
+6.25% |
| 2007-12-31 | CN¥1.17 Billion ≈ $170.79 Million |
+5.24% |
| 2006-12-31 | CN¥1.11 Billion ≈ $162.28 Million |
+44.23% |
| 2005-12-31 | CN¥768.89 Million ≈ $112.51 Million |
+6.12% |
| 2004-12-31 | CN¥724.52 Million ≈ $106.02 Million |
+6.31% |
| 2003-12-31 | CN¥681.54 Million ≈ $99.73 Million |
-0.17% |
| 2002-12-31 | CN¥682.71 Million ≈ $99.90 Million |
+72.17% |
| 2001-12-31 | CN¥396.54 Million ≈ $58.03 Million |
+21.98% |
| 2000-12-31 | CN¥325.09 Million ≈ $47.57 Million |
+11.81% |
| 1999-12-31 | CN¥290.76 Million ≈ $42.55 Million |
+44.08% |
| 1998-12-31 | CN¥201.81 Million ≈ $29.53 Million |
+13.53% |
| 1997-12-31 | CN¥177.76 Million ≈ $26.01 Million |
+208.06% |
| 1996-12-31 | CN¥57.70 Million ≈ $8.44 Million |
+8.36% |
| 1995-12-31 | CN¥53.25 Million ≈ $7.79 Million |
+12.16% |
| 1994-12-31 | CN¥47.47 Million ≈ $6.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Humanwell Healthcare Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1071623256858.0% over the analyzed period, indicating profitable operations and earnings retention.
Humanwell Healthcare Group Co Ltd Net Assets Breakdown (December 2025)
Humanwell Healthcare Group Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥10.72 Billion | 56.66% |
| Other Components | CN¥8.20 Billion | 43.34% |
| Total Equity | CN¥18.91 Billion | 100.00% |
Humanwell Healthcare Group Co Ltd Competitors by Market Cap
The table below lists competitors of Humanwell Healthcare Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BillionToOne, Inc. Class A Common Stock
NASDAQ:BLLN
|
$4.66 Billion |
|
Zhejiang Hailiang Co Ltd
SHE:002203
|
$4.66 Billion |
|
FLSmidth & Co.
CO:FLS
|
$4.67 Billion |
|
Iridium Communications Inc
NASDAQ:IRDM
|
$4.67 Billion |
|
Piper Sandler Companies
NYSE:PIPR
|
$4.66 Billion |
|
Xian Sunresin New Materials Co Ltd
SHE:300487
|
$4.66 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
$4.65 Billion |
|
Insight Enterprises Inc
NASDAQ:NSIT
|
$4.64 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Humanwell Healthcare Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,623,819,000 to 18,913,313,553, a change of 1,289,494,553 (7.3%).
- Net income of 1,855,334,434 contributed positively to equity growth.
- Dividend payments of 1,055,616,317 reduced retained earnings.
- Other factors increased equity by 489,776,436.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.86 Billion | +9.81% |
| Dividends Paid | CN¥1.06 Billion | -5.58% |
| Other Changes | CN¥489.78 Million | +2.59% |
| Total Change | CN¥- | 7.32% |
Book Value vs Market Value Analysis
This analysis compares Humanwell Healthcare Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 304.91x to 1.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | CN¥0.06 | CN¥19.51 | x |
| 1995-12-31 | CN¥0.07 | CN¥19.51 | x |
| 1996-12-31 | CN¥0.08 | CN¥19.51 | x |
| 1997-12-31 | CN¥0.23 | CN¥19.51 | x |
| 1998-12-31 | CN¥0.25 | CN¥19.51 | x |
| 1999-12-31 | CN¥0.37 | CN¥19.51 | x |
| 2000-12-31 | CN¥0.41 | CN¥19.51 | x |
| 2001-12-31 | CN¥0.42 | CN¥19.51 | x |
| 2002-12-31 | CN¥0.68 | CN¥19.51 | x |
| 2003-12-31 | CN¥0.72 | CN¥19.51 | x |
| 2004-12-31 | CN¥0.77 | CN¥19.51 | x |
| 2005-12-31 | CN¥0.83 | CN¥19.51 | x |
| 2006-12-31 | CN¥1.25 | CN¥19.51 | x |
| 2007-12-31 | CN¥1.18 | CN¥19.51 | x |
| 2008-12-31 | CN¥1.29 | CN¥19.51 | x |
| 2009-12-31 | CN¥2.09 | CN¥19.51 | x |
| 2010-12-31 | CN¥2.07 | CN¥19.51 | x |
| 2011-12-31 | CN¥2.74 | CN¥19.51 | x |
| 2012-12-31 | CN¥3.05 | CN¥19.51 | x |
| 2013-12-31 | CN¥4.31 | CN¥19.51 | x |
| 2014-12-31 | CN¥4.08 | CN¥19.51 | x |
| 2015-12-31 | CN¥6.27 | CN¥19.51 | x |
| 2016-12-31 | CN¥7.60 | CN¥19.51 | x |
| 2017-12-31 | CN¥10.00 | CN¥19.51 | x |
| 2018-12-31 | CN¥8.31 | CN¥19.51 | x |
| 2019-12-31 | CN¥7.53 | CN¥19.51 | x |
| 2020-12-31 | CN¥7.69 | CN¥19.51 | x |
| 2021-12-31 | CN¥8.01 | CN¥19.51 | x |
| 2022-12-31 | CN¥9.32 | CN¥19.51 | x |
| 2023-12-31 | CN¥10.46 | CN¥19.51 | x |
| 2024-12-31 | CN¥10.87 | CN¥19.51 | x |
| 2025-12-31 | CN¥11.59 | CN¥19.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Humanwell Healthcare Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.81%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.74%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.94x
- Recent ROE (9.81%) is below the historical average (10.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 26.11% | 21.94% | 0.55x | 2.16x | CN¥7.26 Million |
| 1995 | 26.33% | 21.34% | 0.57x | 2.18x | CN¥8.16 Million |
| 1996 | 25.81% | 16.46% | 0.60x | 2.61x | CN¥8.73 Million |
| 1997 | 10.85% | 19.32% | 0.35x | 1.62x | CN¥1.40 Million |
| 1998 | 10.54% | 13.76% | 0.38x | 2.01x | CN¥964.01K |
| 1999 | 7.01% | 13.60% | 0.28x | 1.81x | CN¥-7.77 Million |
| 2000 | 12.52% | 19.08% | 0.36x | 1.80x | CN¥7.24 Million |
| 2001 | 9.46% | 11.60% | 0.24x | 3.34x | CN¥-1.60 Million |
| 2002 | 4.03% | 3.45% | 0.39x | 2.99x | CN¥-28.52 Million |
| 2003 | 6.02% | 5.37% | 0.34x | 3.31x | CN¥-20.31 Million |
| 2004 | 7.43% | 6.79% | 0.32x | 3.37x | CN¥-13.89 Million |
| 2005 | 8.85% | 6.88% | 0.37x | 3.52x | CN¥-6.68 Million |
| 2006 | 11.62% | 13.54% | 0.33x | 2.60x | CN¥14.31 Million |
| 2007 | 7.42% | 9.85% | 0.29x | 2.58x | CN¥-24.12 Million |
| 2008 | 7.77% | 7.63% | 0.40x | 2.54x | CN¥-22.42 Million |
| 2009 | 11.47% | 15.15% | 0.40x | 1.88x | CN¥25.87 Million |
| 2010 | 11.09% | 9.82% | 0.52x | 2.17x | CN¥21.23 Million |
| 2011 | 11.33% | 8.35% | 0.58x | 2.33x | CN¥35.30 Million |
| 2012 | 13.43% | 7.64% | 0.68x | 2.60x | CN¥103.75 Million |
| 2013 | 9.62% | 6.95% | 0.62x | 2.24x | CN¥-16.44 Million |
| 2014 | 9.57% | 6.41% | 0.58x | 2.58x | CN¥-20.51 Million |
| 2015 | 8.30% | 6.50% | 0.55x | 2.30x | CN¥-134.26 Million |
| 2016 | 8.29% | 6.75% | 0.47x | 2.63x | CN¥-171.72 Million |
| 2017 | 15.30% | 13.39% | 0.43x | 2.68x | CN¥716.34 Million |
| 2018 | -21.79% | -12.65% | 0.52x | 3.34x | CN¥-3.44 Billion |
| 2019 | 8.28% | 3.86% | 0.60x | 3.55x | CN¥-174.48 Million |
| 2020 | 9.45% | 4.86% | 0.64x | 3.05x | CN¥-58.20 Million |
| 2021 | 10.17% | 6.41% | 0.58x | 2.73x | CN¥22.32 Million |
| 2022 | 16.52% | 11.12% | 0.62x | 2.40x | CN¥980.41 Million |
| 2023 | 12.52% | 8.70% | 0.68x | 2.12x | CN¥430.12 Million |
| 2024 | 7.55% | 5.23% | 0.70x | 2.07x | CN¥-432.64 Million |
| 2025 | 9.81% | 7.74% | 0.65x | 1.94x | CN¥-36.00 Million |
Industry Comparison
This section compares Humanwell Healthcare Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,554,577,785
- Average return on equity (ROE) among peers: 7.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Humanwell Healthcare Group Co Ltd (600079) | CN¥22.44 Billion | 26.11% | 0.66x | $4.66 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.45 Billion | 1.52% | 1.57x | $485.12 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $576.00 Million | 3.15% | 0.28x | $363.11 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.12 Billion | 13.25% | 0.26x | $4.79 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $623.47 Million | 16.22% | 0.40x | $2.70 Billion |
| Wedge Industrial Co Ltd (000534) | $654.70 Million | 1.92% | 0.87x | $1.28 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $184.00 Million | 12.94% | 0.09x | $14.40 Billion |
| Hainan Haiyao Co Ltd (000566) | $2.20 Billion | -4.84% | 2.35x | $770.77 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $728.20 Million | 3.47% | 0.58x | $275.43 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.67 Billion | 4.59% | 1.27x | $925.00 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $2.34 Billion | 20.86% | 0.40x | $3.01 Billion |
About Humanwell Healthcare Group Co Ltd
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for pa… Read more